Table 3 Cox regression models in predicting cardiovascular outcomes according to both hsCRP levels (mg/L) and hypertension status at baseline

From: High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes

Category (n, Events/Subjects)

Hazards ratio (95% CI)

 

Unadjusted model

Model 3

Model 4

All endpoint events

    HsCRP <1/-HTNa (54/627)

1.00

1.00

1.00

    HsCRP 1–3/-HTN (62/599)

1.19 (0.83–1.71)

1.19 (0.82–1.71)

1.05 (0.73–1.53)

    HsCRP >3/-HTN (38/351)

1.23 (0.81–1.86)

1.22 (0.80–1.85)

1.05 (0.69–1.61)

    HsCRP <1/+HTN (108/893)

1.46 (1.05–2.02)b

1.39 (0.99–1.92)

1.30 (0.93–1.81)

    HsCRP 1–3/+HTN (156/1110)

1.63 (1.19–2.22)c

1.56 (1.14–2.12)c

1.30 (0.95–1.79)

    HsCRP >3/+HTN (112/711)

1.86 (1.35–2.58)c

1.78 (1.29–2.47)c

1.51 (1.09–2.11)b

Hard endpoint events

    HsCRP<1/-HTNa (18/627)

1.00

1.00

1.00

    HsCRP 1–3/−HTN (18/599)

1.01 (0.52–1.94)

1.01 (0.53–1.94)

0.80 (0.40–1.59)

    HsCRP>3/−HTN (21/351)

2.00 (1.06–3.79)b

1.95 (1.03–3.70)b

1.61 (0.84–3.08)

    HsCRP<1/+HTN (41/893)

1.65 (0.95–2.86)

1.49 (0.86–2.60)

1.41 (0.81–2.46)

    HsCRP 1–3/+HTN (68/1110)

2.05 (1.22–3.45)c

1.87 (1.11–3.15)b

1.51 (0.89–2.57)

    HsCRP >3/+HTN (52/711)

2.52 (1.47–4.30)c

2.28 (1.33–3.91)c

1.89 (1.10–3.27)b

  1. Model 3, age-adjusted and sex-adjusted. Model 4, additionally adjusted for current smoking, diabetes mellitus, Gensini score, left ventricular ejection fraction, triglyceride, low-density lipoprotein cholesterol, statin use (Yes or No) and antihypertensive drugs use (Yes or No). HsCRP high-sensitivity C-reactive protein, HTN hypertension
  2. aReference group
  3. bp  < 0.05
  4. cp  < 0.01
Back to article page